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Abstract
Chemotherapeutic agents have been used for the treatment of numerous types of tumors with great
success. Cisplatin and Doxorubicin are among the well-known chemotherapeutic drugs that
showed efficacy against various types of cancers. However, cell resistance and major side effects
like chemotherapy-induced peripheral neuropathy (CIPN) are limiting factors in using these
compounds. Using a combination or adjuvant compounds with anti-angiogenic effects is one of
the strategies suggested to decrease resistance or ameliorate chemotherapeutic toxicity. The
present study investigated the anti-angiogenic effects of Cisplatin and Doxorubicin alone and
combined with Sulfated non-anticoagulant heparin (S-NACH), a low molecular weight heparin
LMWH that has anti-angiogenic and anti-tumor properties, or OT-515, a tempol congener-derived
molecule that might act on inhibiting tumor proliferation and angiogenesis. The compounds' ability
to enhance the effects of chemotherapeutic agents and decrease the doses used was tested in-vitro
and in-vivo through using a chick chorioallantoic membrane (CAM) model, in the presence and
absence, of tumor cells. To elucidate the mechanism of anti-angiogenic effect of the compounds,
their impact on endothelial cells was studied by performing cytotoxicity assays using HUVEC and
mouse endothelial cells. The results showed that combinations of Cisplatin and Doxorubicin with
S-NACH or OT-515 had enhanced anti-tumor and anti-angiogenic effects than individual
treatments. This suggests that OT-515 and S-NACH provide promising adjuvant therapy to reduce
doses of traditional chemotherapeutic agents and ameliorate their adverse effects.

Keywords
Angiogenesis, Doxorubicin, Cisplatin, Chick Chorioallantoic Membrane (CAM), OT-515, SNACH, CIPN
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Introduction

The use of cancer chemotherapy has expanded over the years to provide effective treatment for
human cancer types. Cancer chemotherapy may, in many case, ameliorate the mortality and
morbidity of cancer patients while improving their quality of life 1. Their side effects including
ototoxicity, nephrotoxicity, and neurotoxicity, are the major limiting factor in their use. To prevent
toxicity and side effects, there is a need for a means of modifying the anti-cancer effects that would
ameliorate adverse side effects.
Angiogenesis is an essential step for the growth and maturation of tissues. Tumor cells require
angiogenesis to provide nutrients and oxygen for growth, expansion, and metastasis. Several
studies have investigated angiogenesis to be well understood as an important therapeutic target for
cancer treatment. Platelet-derived growth factor (PDGF) and other growth factors especially
vascular endothelial growth factor (VEGF) and Fibroblast growth factor (FGF) are known as
powerful angiogenic agents that mediate angiogenesis through different mechanisms 2,3 Inhibiting
angiogenesis through using chemotherapeutics that affect angiogenesis as well as using an antiangiogenic adjuvant therapy are both strategies adopted to treat cancer with decreased side effects.
Sulfated non-anticoagulant heparin (S-NACH), a low molecular weight heparin LMWH that has
no effect on the systemic coagulation factors but was known to release tissue factor pathway
inhibitor protein that inhibits TF/VIIa complex. S-NACH has been shown to inhibit tumor
proliferation, metastasis in addition to the anti-angiogenic effect that suggests different
mechanisms in tumor suppression 4. OT-515 is a tempol congener-derived molecule that is an
enhanced version of OT-404. OT-404 is known to enhance the efficiency of different
chemotherapeutic agents, inhibit cancer cell proliferation, angiogenesis and protect neuronal cells
1

through inhibiting both OS and NFкB activity 5. These agents have been suggested as potential
anti-neoplastic agents or as adjuvants to cancer chemotherapy. The study's objectives are to
evaluate the direct anti-angiogenic activity of chemotherapeutics and the effect of combining SNACH or OT-515 as adjuvant therapy to enhance the activity and minimize side effects.
In this study, the anti-angiogenic effects of Cisplatin and Doxorubicin were tested directly using
the CAM model. Their ability to inhibit both tumor growth and tumor-mediated angiogenesis
relied on using a CAM model implanted with the SH-SY5Y neuroblastoma cell line in Geltrex.
Enhancement of this activity using OT-515 or S-NACH in combination with lower concentrations
of the chemotherapeutic agents was also investigated in this model. The mechanism of action of
whether this was due to direct effects on endothelium was elucidated by testing for direct
cytotoxicity of the compounds on human umbilical vein endothelial cells (HUVEC).

1.

Hypothesis

Anti-tumor activity of Cisplatin and Doxorubicin are mediated, in part, through the inhibition
of angiogenesis, an activity enhanced by OT-515 and/ or S-NACH, while allowing dose
reduction (and toxicity) of chemotherapeutic agents.

1.1.

Aims

1- Establish the anti-cancer and anti-angiogenic activity of Cisplatin and Doxorubicin
and test agents in the CAM model.

2

2- Determine the anti-angiogenic activity of OT-515 and/or S-NACH, alone, and their
potential to enhance chemotherapeutic-mediated anti-angiogenic and anti-cancer
activity.
3- Determine the anti-angiogenic action of OT-515 and/or S-NACH, together with
chemotherapeutic, against endothelial proliferation while reducing the doses of
chemotherapeutic required.
1.2.

Expected outcomes

1- It is anticipated that both Cisplatin and Doxorubicin will have potent antiangiogenic action and will inhibit the new vessels formation in CAM compared to
VEGF and phosphate buffer controls. In addition, we hypothesize that OT-515 and/or
S-NACH will have an additive or synergistic effect on inhibiting angiogenesis when
combined with Cisplatin or Doxorubicin.
2- It is anticipated, based on earlier reports, that both OT-515 and S-NACH are likely
to have some anti-angiogenic activity of their own while also enhancing Doxorubicin
and Cisplatin anti-angiogenic and anti-tumor activity against that induced by
neuroblastoma SH-SY5Y implanted CAM model.
3- It is anticipated that the compounds will reduce the need for high doses
(concentrations) of the chemotherapeutic agent(s), often dose-limiting, thereby
improving anti-tumor activity and safety.

3

Figure 1. Anti-angiogenic adjuvant therapy as a strategy to lower the used doses of
chemotherapy and avoid their side effects, mainly chemotherapy-induced peripheral neuropathy.

4

Chapter One: Literature Review

1.

Angiogenesis in Cancer

Angiogenesis is the process of generating new capillary blood vessels. It is a pivotal
mechanism for many physiological and pathological events. Physiologically, angiogenesis
is required during embryonic development, wound healing, and menstruation cycle with a
high degree of regulatory control. Pathological events are often associated with unregulated
angiogenesis, as seen in cancer. Tumor growth and metastasis require angiogenesis to
support the tumor site with an extensive network of capillaries for the proper nourishment
and waste removal 6–8. Pro-angiogenic and anti-angiogenic factors secreted by endothelia,
tumor cells, and the surrounding stroma act as modulators of this process. Knowing these
mediators is crucial for understanding the mechanism of the process and the appropriate
methods for controlling the unregulated events. In that context, different proteins have been
identified as activators of angiogenesis, such as vascular endothelial growth factor (VEGF),
basic fibroblast growth factor (bFGF) -α and -β, tumor necrosis factor (TNF)-α, plateletderived endothelial growth factor (PEGF), epidermal growth factor (EGF), interleukin
(IL)-8, other specific growth factors and cytokines

6,9,10

. However, the blood vessel

remodeling process is complex, targeting one or more pathways that might activate another
mode leading to disease progression. Hence, drugs with anti-angiogenic properties
targeting the common downstream signaling pathways would effectively suppress tumor
progression, especially if these targets are excessively up-regulated or activated in tumor
cells, compared to healthy tissue 10.

5

1.1.

Factors involved in angiogenesis
1.1.1.

Vascular Endothelial Growth Factor (VEGF)

VEGF is one of the most potent angiogenic cytokines that play a critical role in vascular
formation in normal and neoplastic tissues. It is secreted as dimeric glycoprotein and
has different isoforms (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E), all of which
bind to specific VEGF receptors (VEGFR). The process of de novo formation of new
blood vessels is called vasculogenesis sprouting9,11. Various genetic and epigenetic
modifications in cancer cells enable the cells to produce high levels of VEGF. Tumor
hypoxia and oncogenes are among the factors that up-regulate the expression of VEGF
in tumor cells and VEGF receptors in tumor endothelial cells. Tumor cells secret VEGF
into the surrounding tissue, stimulating endothelial cells on binding to its receptor on
the surface of endothelial cells. This binding activates protein signaling pathways that
activate the transcription of specific genes needed for new endothelial cell growth and
tumor progression12 (Fig. 2). In addition, the VEGF family has a highly conserved
structure among species with high specificity for the vascular endothelium, which
makes it a suitable factor to be used in various in vitro and in vivo models to stimulate
angiogenesis13.
bFGF is a member of the FGF family that binds to receptor tyrosine kinases leading to
activation of the tyrosine kinase signal transduction pathways. The downstream
signaling cascade leads to the differentiation of endothelial cells through a mechanism
not fully understood. bFGF plays an essential role in tumor growth and angiogenesis
and is crucial to converting hormone-dependent-cancers to hormone-independent
entities6.
6

Figure 2: A schematic illustration of the factors involved in tumor angiogenesis14

1.1.2.

Cytokines and chemokines in angiogenesis

It is now fully accepted that tumor expansion after tumorigenesis can be hampered,
leading to tumor dormancy. The expansion of the tumor occurs following the
angiogenesis transition in which the tumor acquires the ability to induce angiogenesis.
The process is complex and tightly controlled by various pro-angiogenic cytokines and
inhibitory factors, as previously mentioned. In addition to the VEGF family, nonspecific and specific growth factors, interleukins also play a role in the process. IL-8

7

was found to be a macrophage-derived pro-angiogenic factor that helps induce the
proliferation of cells and consequently induction of angiogenesis 15.
Indirect-acting factors also play a role; they affect angiogenesis by releasing directacting factors. For example, TNF-α is among the most studied factors as it increases
VEGF expression, as well as that of its receptors, and IL-8 and bFGF in endothelial
cells7. IL-1 is another indirect activator as it induces the expression of VEGF. However,
it is not the only mechanism as IL-1β is also known to induce the expression of
Angiopoietin-1. While IL-6 expression is associated with angiogenesis that is required
for the development of ovarian follicles, in cancer, IL-6 and VEGF levels are
correlated, indicating that IL-6 likely regulates VEGF expression as an indirect
modulation effect on angiogenesis15,16 (Fig. 2).
It should also be noted that secretion of these cytokines can alter the expression of
adhesion molecules and surface markers on endothelial cells. Adhesion receptor
integrin αvβ3 is among the selectively expressed markers. The interaction between
integrin αvβ3 and its receptor activates specific signals that increase the survival of new
endothelial cells6.

1.1.3.

NFкB and angiogenesis

Nuclear factor kappa B (NFкB) is a group of proteins that are structurally related and
representing a family of inducible transcription factors that regulate a large array of
genes involved in immune and inflammatory response processes. The family is
composed of five members, including NFкB1 (p50), NFкB2 (p52), RelA (p65), RelB,
8

and c-Rel, that form various combinations of dimers. The NFкB proteins are normally
sequestered in the cytoplasm due to the association with inhibitor kappa B (IкB)
proteins 17,18. When cells are stimulated, IкB is phosphorylated and degraded by IкBkinase complex(IкK), followed by NFкB translocation to the nucleus and binding to
specific promoter sequences where it regulates gene expression. The NFкB target genes
are involved in different functions, including survival, proliferation, and inflammation
(Figure 3)19.
The role of NFкB signaling in angiogenesis has been investigated and connected to
multiple aspects of angiogenesis. In some instances, the activation of NFкB appears to
inhibit angiogenesis, but the mechanism is not fully understood. However, its
regulation of extracellular matrix (ECM) might play a role in angiogenesis early events
as vascular basement membrane degradation and ECM remodeling is an initial even in
angiogenesis20.

9

Figure 3. NFкB pathway. The stimulation of cell surface receptors activates the IкK
complex and dissociate NFкB from IкB to translocate to the nucleus and turn on target
genes19.
1.2.

Chemotherapeutics and angiogenesis

Conventional chemotherapeutic agents such as platinum compounds, anthracyclins, and
taxanes are well established as effective agents against breast, colorectal, ovarian, lung,
and testicular cancers. However, they are known to act on all dividing cells, damaging
normal tissues and manifesting toxic effects5,21. Cisplatin is a platinum compound, a cellcycle non-specific anti-tumor drug. It is one of the most effective chemotherapeutic drugs
that can be used against various types of cancers and improves overall survival. Its anti10

cancer action is mediated through inducing DNA cross-linking, DNA damage, and cell
apoptosis. The lack of cisplatin cell-specificity leads to some significant adverse effects
such as nephrotoxicity, neurotoxicity, and ototoxicity

21,22

. Doxorubicin is another

traditional chemotherapeutic agent, an anthracycline drug that was developed to be used in
lung, gastric, ovarian, thyroid, breast, sarcoma, and pediatric cancers. Doxorubicin toxicity
is the major limiting factor for its use, particularly its cardiotoxicity23. To prevent toxicity
and side effects, there is a need for anti-cancer agents that target only tumor cells and can
be used as combination therapy or a means of enhancing anti-cancer effects while
ameliorating adverse side effects.

1.3.

Chemotherapeutics in Neuroblastoma

Over the years, studies suggest that Cisplatin and Doxorubicin can target several cancers,
including neuroblastoma. Neuroblastoma is the most frequent extracranial solid tumor in
children. It accounts for more than 7% of malignancies in children with less than 40%
survival24. Both Cisplatin and Doxorubicin were examined as commonly used in the
protocols of the treatment of neuroblastoma. They were reported to induce vessel formation
in different angiogenesis models when used in low doses, compared to an inhibited
angiogenic effect at higher doses. This angiogenesis activation effect was also confirmed
by examining samples derived from neuroblastoma patients25. In contrast, metronomic
doses of Cisplatin were reported to affect angiogenesis through inhibiting blood vessel
endothelial cells

22,26

. However, the mechanisms of action of Cisplatin and Doxorubicin
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and whether their effect on angiogenesis is direct through endothelial toxicity or
pharmacological through inhibition of growth factor production is unclear.
Furthermore, human-derived neuroblastoma cells are used in the in vitro neurotoxicity
assays27. Neuroblastoma cell lines were also reported to be more sensitive to chemotherapy
than normal endothelial cells, which require higher doses to reach IC5025. Taken together,
more investigations of the effect of chemotherapeutics on neuroblastoma tumors and their
effects on angiogenesis are required. The present study also elected to use neuroblastoma
cells because of the neuropathy often associated with chemotherapy.

1.4.

OT-404/ OT-515 and Angiogenesis

OT-404 is a small molecule precursor to tempol, a piperidine nitroxide that is known to
have anti-cancer functions. It was reported to inhibit the proliferation of tumor cells, as
well as angiogenesis and enhance the sensitivity of tumors to anti-cancer agents. A
proliferation test on different cell lines showed that OT-404 has anti-proliferative activity
against various cell lines. The molecule inhibited the proliferation of both chemo-sensitive
and -resistant cells and enhanced the sensitivity of cancer cells to different
chemotherapeutics, including Doxorubicin. Its effect on angiogenesis was studied using
chorioallantoic membrane (CAM) assay stimulated with VEGF, and it showed inhibition
of the pro-angiogenic response to VEGF5.
A series of studies at the Pharmaceutical Research Institute (PRI) investigated the effect of
OT-404 on NFкB and oxidative stress. The western blot analysis showed OT-404 increase
cytoplasmic p65/nuclear p65 ratio with an increase in inhibitor IкB level, indicating that
12

OT-404 restrict NFкB to the cytoplasm and inhibits its activation translocation to the
nucleus (Fig. 4A). OT-404 has also been shown to reduce the fluorescence resulted from
stimulating RGC5 cells with H2O2 in the presence of the H2DCFDA fluorogen that
fluoresces in the presence of oxidation. This indicates that OT-404 does indeed modulate
oxidative stress (Fig. 4B)28. In addition, OT-404 combined with Cisplatin attenuates acute
hyperplasia (increased sensitivity to pain) caused by Cisplatin in rats. The study also
provided evidence that OT-404 can give protection against cisplatin-induced peripheral
neuropathy28.
Although oxidative stress caused by reactive oxygen species (ROS) was believed to limit
cancer initiation and progression by killing cancer cells, ROS also promote cancer initiation
by promoting different aspects of tumor development and progression29. Oxidative stress
can activate signaling pathways, including NFкB and HIF-1 transcription factors leading
to the expression of growth factors, inflammatory cytokines, and chemokines that promote
mutagenesis, inflammation, and cell survival. Moreover, ROS production stabilizes HIF1α protein that induces angiogenic factors and increases VEGF level, ultimately leading to
angiogenesis. Therefore, targeting oxidative stress offers an opportunity for cancer
prevention and treatment 30–32.
OT-515, used in the present work, is another tempol derivative that possesses the same
properties as OT-404 with higher potency, as suggested by the preliminary studies.
However, investigations of the anti-tumor and anti-angiogenic effects of OT-515 are
required as a potential anti-cancer adjuvant compound and is the focus of this thesis.

13

A

B

Figure 4. Prelimenary results of OT-404
A) Western blot analysis show that OT-404 retained higher level of P65 and IкB in the
cytoplasm compared to their nuclear level indicating the inhibition of NFкB, B) OT-404
attenuated fluorescence intensity indicating an inhibition activity of oxidative stress in
response to H2O2 (Provided by S. A. Mousa, PRI, NY).

1.5.

S-NACH and angiogenesis

Heparin and its low molecular weight heparin (LMWH) derivatives -apart from their anticoagulant effects- are increasingly shown to possess anti-inflammatory and immunemodulatory properties 33,34. Different potential mechanisms of this anti-inflammatory effect
have been discussed, such as the binding of heparin to various cytokines and chemokines
and neutralizing cytokines at the inflammation site. Numerous studies demonstrate that
heparin administration decreases cytokines such as IL-6, IL-8, and TNF-α. Another
possible mechanism is inhibiting NFκB by preventing its translocation to the nucleus. It
was also shown to induce apoptosis by modulating the TNF-α and NF-κB

34,35

. LMWH

also inhibits tumor proliferation and metastasis by inhibiting Tissue Factor (TF)/VII
14

pathway, which is known to promote tumor metastasis and angiogenesis36–38. However, the
anti-coagulant property of heparin and its LMWH derivatives is a major obstacle that
hinders their use due to the risk of bleeding

33,39

. The concept of formulating derivatives

from LMWH that are devoid of anti-coagulant properties has emerged to prompt its antiinflammatory properties 33,39,40.
Sulfated non-anticoagulant LMWH (S-NACH) is an oxidized sulfated ultra-LMWH
derivative with all the properties of LMWH with low to no systemic anti-coagulant activity.
It can be administered in high doses without bleeding complications41. S-NACH releases
tissue factor pathway inhibitor (TFPI) protein that inhibits TF/VII. Recently, S-NACH
showed a protective effect on endothelial cells against thrombo-inflammation through this
TFPI pathway, together with nitric oxide and other protective factors42,43. It also evidenced
potent anti-proliferative and anti-angiogenic effects against tumor cells with minimal
effects on hemostasis. S-NACH also has anti-metastatic activity, suggesting its use as a
potent adjuvant therapy in cancer treatment

4,36,44

. These multimodal mechanisms of S-

NACH against cancer make it another potential anti-cancer compound that needs to be
studied as an adjuvant treatment in combination with chemotherapy.
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2.

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the common side effects
that develop with the use of various traditional chemotherapeutic agents such as taxanes,
platinum compounds, and vinca alkaloids. Studies reported that the incidence rates of CIPN
range between 19% to more than 85% according to the type of cancer, the used
chemotherapeutic, duration of therapy, and whether the patient receives an individual
chemotherapeutic agent or a combination of two compounds45,46. CIPN is considered a
major dose-limiting factor for the use of chemotherapeutics as patients must stop the
treatment course or lower the chemotherapeutic doses used to avoid the pain. This
eventually affects the clinical outcomes of cancer treatment and is considered a huge
burden in cancer therapy.

2.1.

Prognosis of CIPN

The symptoms of CIPN differ depending on the type of neurons affected (automatic, motor,
or sensory), and they may be reversible or irreversible47. Usually, it occurs with long nerves
and with a symmetric distribution. The exact mechanism of the development of CIPN is
not fully understood but is generally believed to involve chemotherapeutic agents' damage
to the microtubules, which affects the peripheral nerves. They also act directly on DNA or
disrupt mitochondria, leading to an interference of the role of microtubules in axonal
transport21. Although no one mechanism is known to be responsible for initiating CIPN,
several factors are involved. Some studies suggested that alterations in the sodium-channel
action potential leading to a prolonged open state of the channel might be a factor as it
16

results in hyper-excitability of sensory neurons with attendant calcium influx. The pathway
involving calcium overload and downstream activation of apoptosis and oxidative stress is
also believed to participate in toxic neuropathy. Activation of NFкB also has a role in the
pathogenesis, and hence, interventions that act on decreasing NFкB or inhibiting oxidative
stress might have a protective effect against CIPN (Fig. 5)21,48,49.

Figure 5: A schematic illustration of CIPN development21
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3.

Chorioallantoic Membrane (CAM) Model of Angiogenesis

Many in vivo and in vitro assays have been developed to study angiogenesis as a hallmark
of cancer progression50. The chick chorioallantoic membrane assay (CAM) is one of the
oldest assays that were commonly accepted and used to study angiogenesis in situ. The test
was developed by Folkman et al. (1975), exploiting the fact that blood vessels expand and
grow on the chorioallantoic membrane of fertilized eggs in the process of chick embryo
development 51. The chorioallantois is formed in the chick embryo between days 4-5 after
fertilization. A network of blood vessels is formed gradually to sustain the development of
organs until the CAM is fully developed by day 10-12. Therefore, the CAM displays robust
angiogenic activity during this period and can respond to any pro-angiogenic stimuli by
establishing new blood vessels or decrease its formation in response to anti-angiogenic
factors52. All these features render the CAM assay a well-established test for investigating
and validating pro-and anti-angiogenic treatments. CAM assay is also an easy and
inexpensive method that is suitable for large-scale screening of angiogenesis. The
technique depends on opening a small window in a fertilized egg to access the avascular
area in the CAM. Controls and treatments are applied using a plastic or filter disc to allow
the release of the compound into CAM. The effect of compounds on vascularization is
determined through imaging the CAM membrane under a microscope to count the
difference in blood vessel branches 53.
In addition, the fact that the chick embryo is not immunocompetent encouraged researchers
to graft different types of cells into the CAM to establish a model for tumor angiogenesis,
allowing the investigation of anti-tumor and anti-angiogenesis properties of compounds.
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Tumor cells are grafted into the CAM between days 8-10, incorporated into a gel matrix,
left to grow for 5-7 days until forming a developed tumor. Tumors are then harvested for
the examination of cancer development, anti-tumor, and anti-angiogenesis effects of
compounds54.
Recently, various modifications have been introduced into these classic CAM assays
revolutionizing their use. Recent studies have used the CAM as a model for testing the antimetastatic capacity of cancer cells and the study of human bone regeneration55,56.
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Chapter Two: Materials and Methods
2.1. Cells and Reagents
The following cell lines, media, and reagents were used in these studies. Human Umbilical
Vein Endothelial Cells HUVEC (Gibco, USA), Human Neuroblastoma SH-SY5Y (gifted
by Zewail University for Science and Technology), mouse endothelial cells C 166 (ATCC,
USA), Human Large Vessel Endothelial Cell Basal Medium M 200 (Gibco, USA), Dulbecco's
Modified Eagle's Medium (DMEM, Lonza, Belgium), Roswell Park Memorial Institute culture
medium (RPMI 1640, Lonza, Belgium), Large Vessel Endothelial Supplement (LVES, 50X,
Gibco, USA), Fetal Bovine Serum (FBS, Life Science Production, UK), Penicillin-

Streptomycin (pen-strep, Lonza, Germany), Phosphate Buffer Saline PBS (Lonza, USA),
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT reagent, Serva,
Germany), dimethyl sulfoxide (DMSO, ≥99.9, molecular weight=78.13 g/mol, Serva),
Geltrex LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Invitrogen,
USA), Vascular Endothelial Growth Factor From Mouse (Sigma Aldrich, Germany).

2.2. Detecting the possible mechanisms of action in-vitro
2.2.1. In vitro cell culture
All cell lines were cultured as monolayers and incubated at 37° and 5% CO2, in a humidified
atmosphere. HUVECs were cultured in M200 supplemented with 2% LVES and 0.5% PenStrip. C 166 and MCF7 cells were cultured in DMEM supplemented with 10% FBS and
1% Pen-Strip, while SH-SY5Y were cultured in RPMI supplemented with 10% FBS and
1% Pen-Strip. Only early passages of primary cells were used, HUVEC passages 2-5 and
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C 166 passages 3-9. All cells were cultured until reaching 70% confluency then passaged
for further use in cell proliferation and tumor grafting assays.
2.2.2. Cells Proliferation
To determine the cytotoxicity of compounds and their effect on cell proliferation, MTT
colorimetric assay was performed as described previously57.
HUVEC normal endothelial cells. Cells were harvested and seeded in 96-well plates,
incubated for 24 hours at 37° C (5% CO2). The culture media was removed at 70-80%
confluence, and cells were washed with PBS. Different treatments were added, and the
mixture was incubated for 72 hours. Then 100μL of MTT (1mg/ml) was added to the cells
and incubated for 4 h. DMSO was then added to solubilize the formed formazan dye. The
produced violet color was measured as the absorbance of each well at 540 nm using a
microplate spectrophotometer system (SPECTROstar Nano, BMG LABTECH, Germany).

2.3. Detecting anti-angiogenic properties
2.3.1. Chick chorioallantoic membrane assay
CAM model was used to elucidate the anti-angiogenic effect of the compounds using PBS
as negative control and comparing them to VEGF as a positive control (Fig. 6). Ten-dayold fertilized chick embryos were incubated at 37 °C. Neovascularization was examined
by CAM assay as previously described 58,59. Using an egg candler, an avascular area of the
egg was marked as the air sac. A small hole in the shell at the air sac was made using a
hypodermic needle, an avascular portion of the embryonic membrane was identified, and
a second hole was made on the long side of the egg over it. Mild suction was applied to the
first hole to move the air sac and allow the CAM to drop. A 1 cm2 window was sectioned
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in the membrane using a drill to expose the vascular zone. A #1 sterilized filter paper disk
(Millipore) was then loaded with the experimental treatments or vehicle controls and then
applied to adhere to the vascular zone. Cisplatin, Doxorubicin, OT-515, and S-NACH were
used and compared in the presence of standard pro-angiogenic stimuli VEGF (2μg/ml).

2.3.2. Microscopic analysis of CAM sections
After three days of incubation, the tissue beneath each filter disk in the CAM was resected,
washed with PBS, and placed in a 35-mm petri dish for microscopic examination. Digital
images of the CAM sections were taken using an Optika stereomicroscope at 10X
magnification and analyzed using ImageJ software. The number of vessel branch points
contained in a circular region equal to the area of each filter disk were counted.

22

Figure 6. Chick Chorioallantoic Membrane Assay (CAM)

2.3.3. Tumor grafting into CAM
Neuroblastoma cells SH-SY5Y were grafted into CAM mixed with Geltrex as a protein
matrix to test the effect of combining S-NACH or OT-515 with Cisplatin or Doxorubicin
on tumor growth. The CAM model was prepared as mentioned above and after creating
the window, tumor cells were grafted as described in previous studies36 (Figure 7).
SH-SY5Y human neuroblastoma cells were introduced as tumor-forming cells. First, A
total of 2 million cells in 20μl medium and 20μl of Geltrex were mixed and added to 10μl
of treatment or PBS control. The suspension was then added to the branch point of the
CAM surrounded with a 1mm silicone ring. To produce more robust tumors, a minor
modification was done to the procedure. The number of cells was increased to 10 million
23

cells per CAM, and 30μl of Geltrex were used instead of 20. On day 7 of incubation, the
tumors were harvested after treatment and examined for their weight and hemoglobin (Hb)
levels. Hb level was determined as a measure of cell vascularity.

2.3.4. Determination of tumor Hb levels
The harvested tumor sections were homogenized, then centrifuged to collect the
supernatant. 50μl of supernatant was then mixed with 50μl Drabkin's reagent and left at
room temperature for 15-30 minutes, then transferred to a 96-well plate to measure the
absorbance at 540 nm using a microplate spectrophotometer system (SPECTROstar Nano,
BMG LABTECH, Germany).
.
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Figure 7. Tumor grafting into CAM
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2.4. Statistical Analysis
Data is represented as mean ± SEM and plotted using GraphPad Prism 8.0.1 software used
for statistical analysis and plot comparisons. CAM experiments were performed in
triplicates with 5-8 embryos per treatment group. Data is evaluated in terms of the average
number of blood vessel branch points per treatment group ± SEM while for the CAM grafts,
mean tumor weight per treatment group ± SEM. One way analysis of variance ANOVA
was used to compare each treatment and control, followed by a post-hoc test to evaluate
the statistical significance between the untreated and treated groups. Statistical significance
was defined as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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Chapter Three: Results
3.1. Effect of combining OT-515 and S-NACH with chemotherapy on the proliferation of
human neuroblastoma cells
Doxorubicin was cultured at different concentrations with human neuroblastoma cell line SHSY5Y for 24, 48, and 72 h. Doxorubicin at a 1µg/ml concentration was particularly potent, mainly
when incubated for 72 h. OT-515 and S-NACH showed an inhibitory effect on the proliferation of
cells after 72 h incubation individually and in combination with Doxorubicin and Cisplatin (Supp
Fig. 1). We have then combined OT-515 and S-NACH with different concentrations of Cisplatin
or Doxorubicin and tested their effect on the proliferation of SH-SY5Y. Results shown in Table.
1 indicate that combining OT-515 or SNACH with Doxorubicin had a more significant antiproliferative effect than individual Doxorubicin even when used at lower concentrations. Cisplatin
combinations had the same results as shown in Table. 2. Moreover, the triple combinations of OT515, S-NACH, and Doxorubicin or Cisplatin had more significant inhibition of proliferation
compared to double combinations, particularly in the case of OT-515 and Cisplatin (Fig. 8).
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Table 1: The significance of combining OT-515 and S-NACH to Doxorubicin on treating SH-SY5Y human neuroblastoma
cells.

Individual
Treatment
(µg/ml)

DOX 0.005

DOX 0.01

DOX 0.05

Avr.
Proliferation
%

81.02808175

70.72780191

21.1749927

P value

Avr.
Avr.
Double Combination
Triple Combination
Proliferation P value
Proliferation P value
(µg/ml)
(µg/ml)
%
%
DOX 0.0025 + NACH 20

67.56134

0.0878

DOX 0.005 + NACH 20

73.34932

0.4603

DOX 0.01 + OT 10

53.36801

<0.0001

DOX 0.01 + NACH 10

38.45634

<0.0001

DOX 0.01 + NACH 20

62.23162

DOX 0.025 +OT 10

0.5372

0.0035

<0.0001

DOX 0.01 + OT 5 +
NACH 10

16.87323

<0.0001

<0.0001

DOX 0.01 + OT 10 +
NACH 20

14.04943

<0.0001

34.27018

<0.0001

DOX 0.017
+OT6.6+NACH 6.6

40.74346

<0.0001

DOX 0.025 + NACH 10

25.72033

<0.0001

DOX 0.05 +OT 10

18.4255

<0.0001

DOX 0.03 +OT
6.6+NACH 6.6

28.289

<0.0001

DOX 0.05 +NACH 10

63.02427

<0.0001

DOX 0.05 + NACH 20

17.58331

<0.0001

DOX 0.05 + OT 10 +
NACH 20

12.21643

<0.0001
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Table 2: The significance of combining OT-515 and S-NACH to Cisplatin on treating SH-SY5Y human neuroblastoma cells.

Individual
Avr.
Treatment Proliferation P value
(µg/ml)
%

CIS 5

CIS 10

CIS 15

81.67211

76.28871

64.37424

Double
Combination
(µg/ml)

Avr.
Proliferation %

P value

CIS 2.5 + OT 10

88.62015

0.9995

CIS 1.6 +OT6.6
+NACH 6.6

111.5037

>0.9999

CIS 2.5 + NACH 10

115.4339

0.9995

CIS 3.3 +OT 6.6+
NACH 6.6

105.6414

>0.9999

CIS 2.5 + NACH 20

87.20412

>0.9999

CIS 5+OT 10

56.98033

<0.0001

CIS 5 + OT 5 + NACH
10

24.32081

<0.0001

CIS 5 + OT 10 +
NACH 20

17.509

<0.0001

CIS 10 + OT 10 +
NACH 20

13.45494

<0.0001

Triple Combination
Avr.
(µg/ml)
Proliferation %

P value

0.6228

0.0918

CIS 5 +NACH 10

79.53361

0.3485

CIS 5 + NACH 20

70.8145

0.0037

CIS 10 + OT 10

50.61439

<0.0001

CIS 10 + NACH 10

63.33389

0.016

CIS 10 + NACH 20

66.49547

0.0004

0.0251
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Doxorubicin- OT515

Cisplatin - OT515

Doxorubicin- SNACH

Cisplatin - SNACH
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Figure 8. Testing the anti-proliferative effect of OT-515 and S-NACH on SH-SY5Y neuroblastoma cells and their enhancing
effect when combined to chemotherapy.
A) Combining OT-515 to Doxorubicin at different concentrations enhanced the anti-proliferation of cancer cells. B) S-NACH at
different concentrations with Doxorubicin. C) OT-515 combinations with Cisplatin. D) S-NACH combinations with Cisplatin.
Data represent mean ± SEM, n = 6-18, One-way ANOVA; **p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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3.2. Anti-angiogenic effects of combining OT-515 and S-NACH with chemotherapy

To investigate the effect of OT-515 and S-NACH and their combinations with chemotherapy on
angiogenesis, we used the CAM assay. We tested the effect of compounds on normative
angiogenesis by applying compounds directly to the CAM membrane using PBS as a negative
control. The pictures showed a slight inhibition of the formation of blood vessels after applying
the filter discs containing the treatments (Fig. 9). However, counting the branch numbers indicated
no significant difference between the treatments and the control (Fig. 10), which suggested that
treatments do not affect normative angiogenesis in the absence of a pro-angiogenic factor or
stimuli. Moreover, when comparing the effects of Doxorubicin and Cisplatin, Cisplatin showed to
have a more potent anti-angiogenic effect on normative angiogenesis as only 1µg/ml of Cisplatin
caused inhibition of approximately 50%. In comparison, we used up to 20µg/ml of Doxorubicin
to achieve the same result.
To induce angiogenesis on CAM, different concentrations of VEGF were applied (Supp Fig. 2).
The results indicated that using a filter disc with VEGF (2µg/ml) on CAM induced blood vessel
formation 2.3 folds (p-value < 0.0001) compared with PBS negative control. The addition of OT515 and S-NACH inhibited the VEGF-stimulated angiogenic effect individually and when
combined with Doxorubicin or Cisplatin (Fig. 11). Counting the blood vessel branches indicated
that both Cisplatin and Doxorubicin also have an anti-angiogenic effect, which significantly
inhibited the pro-angiogenic response caused by VEGF (p-value < 0.0001). Double and triple
combinations of OT-515, S-NACH, and Doxorubicin or Cisplatin significantly inhibited the proangiogenic response as well (Fig. 12). Finally, although we used half the doses of chemotherapy
in the combinations, the inhibitory effect was consistent, indicating that both OT-515 and S-NACH
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enhance the anti-angiogenic effect of chemotherapy, opening a room for reducing the used
therapeutic doses.
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Figure 9. Effect of OT-515 and SNACH combined to chemotherapy on normative angiogenesis using check
CAM assay.
Pictures were taken under and Optika stereomicroscope at 10x magnification.
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Figure 10. Normative angiogenesis on chick CAM assay and its inhibition by OT-515 and SNACH
combined to chemotherapy.
Treatments were added, and vessel branch number was counted using Imagej. Data normalized to PBS
negative control and presented as % inhibition of PBS (100%). n= 5 CAMs per group.
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Figure 11A and B. Effect of OT-515 and SNACH combined with doxorubicin on VEGF-induced
angiogenesis using check CAM assay.
Pictures were taken under and Optika stereomicroscope at 10x magnification. PBS is negative control, all other
groups were first treated with 2µg/ml VEGF to induce angiogenesis A) OT-515 and SNACH were combined
to Doxorubicin, B) combinations with Cisplatin. n= 3-8 CAMs per group.
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B

Figure 12. Effect of OT-515 and SNACH combined to chemotherapy on VEGF-induced angiogenesis
using check CAM assay.
Pictures were taken under and Optika stereomicroscope at 10x magnification. PBS is negative control, all other
groups were first treated with 2µg/ml VEGF to induce angiogenesis A) OT-515 and SNACH were combined
to Doxorubicin, B) combinations with Cisplatin. n= 3-8 CAMs per group.
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Figure 13. Inhibition by OT-515 and SNACH combined to chemotherapy of VEGF-induced
angiogenesis using check CAM assay.
All treatments are normalized to PBS negative control; all groups were first treated with 2µg/ml
VEGF to induce angiogenesis then treatments were added, and vessel branch number was
counted using Imagej. A) OT-515 combined to Doxorubicin, B) S-NACH combined to
Doxorubicin, C) OT-515 combined to Cisplatin, D) S-NACH combined to Cisplatin. Data
represented as % inhibition of branch number (PBS = 100%), Doses represented as (µg/ml)
which is equivalent to (0.02 µg/CAM), n= 3-8 CAMs per group. Significant reductions
analyzed with One-way ANOVA; **p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
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3.3. Inhibition of tumor growth and tumor angiogenesis in the CAM model

We used the neuroblastoma grafted CAM model to investigate the in-vivo effect of OT-515,
SNACH, and their combinations on tumor angiogenesis and growth. We first introduced 2*106
neuroblastoma cells SH-SY5Y into CAM using Geltrex as a protein matrix to allow the growth of
tumors. OT-515, S-NACH were applied individually and combined with Doxorubicin and
Cisplatin using Geltrex as negative control and SH-SY5Y cells in media as a positive control.
Pictures showed a slight inhibition of the formed tumors when treated with the compounds (Fig.
13). However, the results of tumor weights did not show a significant inhibitory effect of the
compounds except for some concentrations of Doxorubicin (Fig. 14). Some modifications were
applied to the protocol to allow the growth of larger tumors to spot the difference.
10*106 cells were introduced into CAM with an increased Geltrex of 50% of the total solution.
Pictures showed tumor size and angiogenesis inhibition when adding the treatments and their
combinations (Fig. 15). Harvesting the tumors also showed the difference in tumor size between
the control, the individual treatments, and the combinations (Fig. 16). The tumor weight results
indicated that the administration of OT-515 and S-NACH, separately or in combination with
Doxorubicin or Cisplatin, significantly inhibited tumor growth (p-value < 0.0001). Using half the
doses of chemotherapy combined with OT-515 or S-NACH had comparable significant inhibitory
effects compared to individual chemotherapy, which confirms previous results (Fig. 17). The triple
combinations showed a slightly enhanced effect than the double combinations.
To investigate the in-vivo effect of treatments on tumor angiogenesis, we used Drabkin's method
to measure the hemoglobin content of the neuroblastoma SH-SY5Y CAM-harvested tumors with
and without the addition of treatments and compared to control hemoglobin (Supp Fig. 3). All
individual treatments showed statistically significant inhibition compared to the control (p-value
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< 0.05). The combinations also showed significant inhibition that exceeded the individual results
(p-value < 0.001) although not reaching significance compared to individual treatments. Triple
combinations also showed an enhanced effect than the double combinations but with no
significance (Fig. 18). However, the doses of chemotherapy used in combinations were half the
doses of individual treatments, which confirms that the addition of OT-515 and S-NACH gives
the major anti-tumor and anti-angiogenesis effect while avoiding the side effects caused by
chemotherapy reducing their doses.
For further verification of the results of CAM tumor growth, we tried the same tumor CAM model
using two different types of human-derived cancer cells, neuroblastoma cells (SH-SY5Y) and
breast cancer cells (MCF-7) with and without Doxorubicin. The results showed an inhibition of
the growth of both tumors, although the growth of SH-SY5Y cells and their inhibition by
Doxorubicin was more significant (Fig. 19).
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Figure 14. Typical Stereomicroscope images (7x) showing the growth of human neuroblastoma tumors on
top of the CAM membranes and the inhibition caused by treatments.
Geltrex is negative control, all other groups Have SH-SY5Y cells at 2*106 cells/CAM.
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Figure 15. Human neuroblastoma tumor growth (SH-SY5Y) in the chick CAM model and the reduction
associated with adding treatment compounds.
Geltrex is a negative control, and all other groups have SH-SY5Y cells at 2*106 Cells/CAM with or without
treatments. Data represent mean ± SEM, n = 3-8 per group. Significant reductions in tumor angiogenesis when
adding treatments compared to control analyzed with One-way ANOVA; ***p < 0.0005, **p< 0.001
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Figure 16. Effect of OT-515 and SNACH combined to chemotherapy on inhibiting the angiogenesis and
growth of human neuroblastoma tumors grafted into CAM membranes.
Images taken with a stereomicroscope at 7x magnification. All groups have SH-SY5Y cells at 10*106
cells/CAM.
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Figure 17. Inhibition of tumor growth of human neuroblastoma tumors grafted into CAM by OT-515
and SNACH combined to chemotherapy.
Geltrex is negative control, and all other groups have SH-SY5Y cells at 10*106 cells/CAM. Treatment’s
concentrations represented as µg/CAM.
45
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Figure 18. Effect of OT515 and SNACH combined to chemotherapy on human neuroblastoma tumor
growth (SH-SY5Y) in the chick CAM model.
Geltrex is a negative control, and all other groups have SH-SY5Y cells at 10*106 Cells/CAM with or without
treatments. A) OT-515 combined to Doxorubicin, B) SNACH combined to Doxorubicin, C) OT-515 combined
to Cisplatin, D) SNACH combined to Cisplatin. Data represent mean tumor weight ± SEM, n = 3-8 per group.
Significant reductions in tumor angiogenesis when adding treatments compared to control analyzed with Oneway ANOVA; ****p < 0.0001
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Figure 19. Hemoglobin content of the harvested tumors from CAM Neuroblastoma implant model,
determined by Drabkin’s method.
Geltrex is a negative control, and all other groups have SH-SY5Y cells at 10*106 Cells/CAM with or without
treatments. A) OT-515 combined to Doxorubicin, B) SNACH were combined to Doxorubicin, C) OT-515
combined to Cisplatin, D) SNACH combined to Cisplatin. Data represented as mean ± SEM, n = 3-8 per group.
Significant reductions in tumor angiogenesis when adding treatments compared to control analyzed with Oneway ANOVA; **p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001

49

200

***

150

**

100
50

SH

-S
Y5
Y

SH

-S
Y5

el
tr
ex
+
D
O
Y
X
C
el
0.
ls
05
M
µg
C
/C
FA
7
M
M
+
C
FD
O
7
X
C
el
0.
ls
05
µg
/C
A
M

0

G

Mean tumor weight  SEM (mg)

P 0.05

Treatment

Figure 20. Human breast cancer (MCF-7) and human neuroblastoma tumor
growth (SH-SY5Y) in the chick CAM model.
Geltrex is a negative control, and all other groups have cells at 2*106 Cells/CAM with
or without treatments. Data represent mean ± SEM, n = 3-5 per group.
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3.4. Anti-proliferative effect of OT-515 and S-NACH combined with chemotherapy on
normal endothelial cells
To elucidate a possible mechanism of the anti-tumor effect of the various treatments, we performed
additional anti-proliferation tests to investigate their activity on the proliferation of normal
endothelial cells. OT-515 and S-NACH significantly inhibited the proliferation of human
endothelial vascular cells (HUVEC) p-value < 0.001 (Fig. 20). Combining OT-515 and S-NACH
with Doxorubicin and Cisplatin showed significant inhibition of proliferation compared to
individual chemotherapy (p-value < 0.0001). These findings suggest that the anti-tumor effect of
OT-515 and S-NACH is due to possible impact on mediators, or responses to mediators, involved
in the formation of blood vessels. The exact mechanism still needs further investigation.
To verify the results, we performed the same assay on mouse endothelial cells (C-166) while also
comparing the inhibitory effect of the treatments to VEGF. We first applied different
concentrations of VEGF on C-166 to determine the physiological dose that induces the
proliferation of endothelial cells in-vitro (Supp Fig. 4). The application of 10ng VEGF
significantly increased the proliferation of C-166 mouse endothelial cells (p-value < 0.05). All the
treatments had a significant inhibition compared to VEGF (p-value < 0.0001). The double
combinations of OT-515 or S-NACH with chemotherapy showed an anti-proliferative effect
significantly more than individual chemotherapy even when using half the dose (Fig. 21). In
addition, using a triple combination of OT-515, S-NACH and Cisplatin had the most significant
inhibition compared to the Cisplatin double combinations (p-value < 0.0001), which was also more
significant than the triple combination with Doxorubicin compared to Doxorubicin double
combinations (p-value < 0.05).
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Figure 21. Proliferation inhibition with OT-515 and S-NACH combined to
chemotherapy on human umbilical vascular endothelial cells (HUVEC).
Data represent mean cell proliferation ± SEM, n = 4-6, One-way ANOVA; ***p <
0.001, and ****p < 0.0001.

52

53

Figure 22. Comparing the anti-proliferative effect of OT-515 and S-NACH combined to chemotherapy with
VEGF-stimulated proliferation on mouse endothelial cells C-166.
A)The anti-proliferation effect of individual treatments compared to negative control as well as to VEGF, B)
Combining OT-515 and S-NACH to Doxorubicin at different concentrations enhanced the anti-proliferation of
cancer cells, C) Triple combinations of Doxorubicin, OT-515 and SNACH, D) OT-515 or S-NACH double
combinations with Cisplatin, E) Triple combinations of Cisplatin compared to CIS-OT, F) Triple combinations of
Cisplatin compared to CIS-SNACH. Data represent mean % cell proliferation ± SEM, n = 6-12, One-way
ANOVA; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
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Chapter Four: Discussion

This study provides evidence that both the tempol derivative OT-515 and the sulfated nonanticoagulant low molecular weight heparin (S-NACH) have anti-tumor proliferation and antiangiogenesis properties. These properties were shown when using the compounds separately or
combined with classical anti-cancer chemotherapy such as Doxorubicin and Cisplatin.
Several classical chemotherapeutics, including Doxorubicin and Cisplatin, are well-known to be
neurotoxic agents and cause chemotherapy-induced peripheral neuropathy (CIPN), which, in many
cases, is a dose-limiting event that and requires discontinuing the treatment21,47,60. Although
several mechanisms of CIPN have been identified, reducing the doses of chemotherapeutics used
in treatment is one of the strategies implicated in CIPN prevention61,62. Moreover, combining
chemotherapy with other adjuvant therapy to treat aggressive tumors is also among the commonly
used strategies to target the tumor with multiple mechanisms and achieve remarkable anti-tumor
response with the lowest side effects. The findings that OT-515 and S-NACH have antiproliferative effects (Supp Fig 1) prompted the investigation of their effect when combined with
lower doses of chemotherapeutics. The data presented in (Fig 8) showed that using a combination
of OT-515 or S-NACH with chemotherapy allowed the use of lower doses of chemotherapy while
getting the same or even enhanced anti-tumor effect. Taken together, these findings suggest that
OT-515 and S-NACH could be used as adjuvant therapy with reduced chemotherapeutic doses to
avoid CIPN.
We performed more investigation of the mechanisms of action of agents and their in situ antitumor effects. The data presented in Figs 12, 17, and 18 indicated that OT-515 and S-NACH
enhance anti-tumor and anti-angiogenesis effects when combined with Doxorubicin or Cisplatin
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in situ. However, further optimization to elicit the optimal dosages are required. Previous studies
have tested the impact of combining OT-404 and S-NACH with chemotherapy with promising
results on the increased uptake and enhanced effect of chemotherapeutics, as well as the role of
tempol derivatives and their ability to reverse the resistance to Doxorubicin in different cell lines.
Resistance is yet another limiting factor of chemotherapy use 36,63 but was not investigated in the
present study. Taken together, OT-515, based on what has been demonstrated with OT-404, and
S-NACH act on tumors through multiple targets, which offer an advantageous technique in
possible treating aggressive tumors and reducing adverse side effects.
This study also demonstrated that OT-515 and S-NACH inhibit the proliferation of VEGFstimulated CAM vasculature and VEGF-stimulated normal endothelial cells such as humanderived HUVECs and mouse-derived C-166 cells, with an enhanced inhibitory effect when
combined with chemotherapy. Therefore, it can be inferred that this significant anti-tumor effect
of the compounds is achieved by inhibiting the proliferation of endothelial cells, arresting vessel
growth, and inhibiting angiogenesis required for tumor progression.
Angiogenesis is a well-known hallmark of cancer progression as it is the process by which tumor
cells are supplied with nutrients. It is a complex process that comprises various factors, enzymes,
and cytokines. VEGF is the main factor inducing angiogenesis by endothelial cells through the
induction of proliferative pathways, chemokines, and cytokines64,65. Anti-angiogenic drugs have
been of great interest for researchers to be translated into the clinic either individually or in
combination with chemotherapy as they appear to have a limited toxic profile and, in many cases,
can target, directly or indirectly, multiple anti-tumor mechanisms66,67. Our findings that OT-515
and S-NACH can inhibit the VEGF-induced angiogenesis are of great importance as they
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demonstrate a new strategy to combine with chemotherapy for superior anti-tumor activity, fewer
toxic effects, and drug resistance.
Several studies reported that anti-angiogenic agents could mediate the CIPN side effects through
unclear mechanism68. In contrast, compounds with anti-angiogenic effects have been shown to
work as neuroprotectors and ameliorate CIPN when used in combination therapy69. Previous work
from our laboratory has indicated that OT-404 can ameliorate CIPN caused by Cisplatin through
a dual anti-oxidant and NFкB inhibitory activity, in addition to its effect on inhibiting TNF-α,
which is involved in the cycle that induces NFкB activation28,70. Taken together, in addition to
having anti-angiogenesis and anti-tumor effects, OT-515 might have a protective effect against
CIPN through ROS and anti-inflammatory pathways. Further studies are required to elucidate the
exact mechanism of action.
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Conclusion and future prospects
This study used a combination of well-established in-vitro and in-vivo models to provide evidence
that OT-515, the tempol derivative, and S-NACH have anti-tumor and anti-angiogenesis effects
and can inhibit multiple pathways of cancer progression. They have a remarkable enhancing
(synergistic?) effect when combined with traditional chemotherapy such as Doxorubicin and
Cisplatin, representing a unique strategy of targeting tumors while reducing doses of
chemotherapeutic required, thereby suggesting a role in reducing toxicity while augmenting anticancer activity. Further investigations are required to define the exact mechanism of action, the
pathways involved, and the impact of the compounds on other tumor types, as well as their in vivo
utility.
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Appendix

Supp Figure 1. Effect of compounds incubation for 24, 48 and 72 h on the proliferation of human
neuroblastoma SH-SY5Y cells.
A) Doxorubicin at different concentrations ranging from 0.005 to 100 µg/ml inhibited cancer cell proliferation to
different degrees. B) OT-515 and S-NACH were combined to Doxorubicin and Cisplatin and incubated with
cells, cell proliferation was measured after 24, 48, and 72 h to determine the degree of inhibition at each time
point. Data represent mean ± SEM, n = 6.
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Supp Figure 2. Effect of different concentrations of VEGF on inducing angiogenesis in
the CAM model.
Data represent mean ± SEM, n = 5 per group, One-way ANOVA; ****p < 0.0001.
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Supp Figure 4. Effect of VEGF different concentrations on the proliferation of mouse
endothelial cells C-166
Data represent mean ± SEM, n = 4-6, One-way ANOVA; *p < 0.05.

70

